Chemistry:A-423,579
From HandWiki
![Stereo, Kekulé, skeletal formula of A-423,579 (({[(3R)-3-amino]}))](/wiki/File:A-423,579.svg)
| |
| Names | |
|---|---|
| IUPAC name
4-[4-[3-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]-3,5-difluorophenyl]benzonitrile
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| |
| |
| Properties | |
| C22H25F2N3O | |
| Molar mass | 385.4502 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.[1][2]
References
- ↑ "In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists". Basic Clin. Pharmacol. Toxicol. 95 (3): 144–52. September 2004. doi:10.1111/j.1742-7843.2004.950307.x. PMID 15447739.
- ↑ "Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy". Inflamm. Res. 54 Suppl 1: S27–9. April 2005. doi:10.1007/s00011-004-0412-z. PMID 15928821.
 |
